CA
NZ
UK
AU
IND
US
…
VYNE Therapeutics Inc., a clinical-stage biopharmaceutical company, focuses on developing proprietary and therapeutics for the treatment of immuno-inflammatory conditions. The company's lead product is VYN201, a locally administered pan- bromodomain and extra-terminal (BET) inhibitor soft drug to address diseases involving multiple, diverse inflammatory cell signaling pathways with low systemic exposure. It also develops VYN202, a BD2-selective oral small molecule BET inhibitor for the treatment of immuno-inflammatory indications. The company was formerly known as Menlo Therapeutics Inc. and changed its name to VYNE Therapeutics Inc. in September 2020. VYNE Therapeutics Inc. was founded in 2003 and is based in Bridgewater, New Jersey.
Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website
A unique technical analysis driven score developed by Kalkine showing momentum in stock prices based on select technical indicators identified.
Vyne Therapeutics Inc is a NASDAQ-listed biopharmaceutical company developing therapeutic candidates intended to address unmet medical needs. Long-term growth may be driven by progress across its development programs, regulatory approvals, potential licensing or partnerships and eventual commercialization, which could support pipeline value and future revenue generation.
Principal risks include clinical and regulatory failure, limited or no commercial revenue, the need for additional financing and resulting dilution, competitive pressures and execution challenges in bringing therapies to market.
Note: The summary and risk score provided above is created by AI and should not be construed as a recommendation of Kalkine.
| Breakdown | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 | 2018-12-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 | 2018-12-31 |
| Income before tax | -33.93M | -73.78M | -255.83M | -73.70M | -51.45M |
| Net income | -33.95M | -73.33M | -255.57M | -70.46M | -51.45M |
| Selling general administrative | 16.39M | 54.48M | 89.54M | 22.48M | 12.19M |
| Gross profit | 0.48M | 11.41M | 19.60M | - | 10.64M |
| Reconciled depreciation | 0.07M | 0.11M | 0.34M | 0.70M | 0.02M |
| Ebit | -34.30M | -68.03M | -113.47M | -76.94M | -54.56M |
| Ebitda | -33.93M | -68.17M | -112.02M | -76.24M | -54.53M |
| Depreciation and amortization | 0.36M | -0.14M | 1.45M | 0.70M | 0.02M |
| Operating income | -34.30M | -68.03M | -113.47M | -76.24M | -54.53M |
| Other operating expenses | 34.77M | 82.79M | 134.47M | 76.24M | 65.17M |
| Interest expense | 10.81M | 5.61M | 4.39M | 2.54M | 3.09M |
| Tax provision | 0.01M | -0.45M | -0.26M | - | - |
| Interest income | - | - | - | - | 3.09M |
| Net interest income | 0.00M | -5.61M | -4.39M | 2.54M | 3.09M |
| Income tax expense | 0.01M | -0.45M | -0.26M | -3.24M | 3.09M |
| Total revenue | 0.48M | 14.76M | 20.99M | 0.00M | 10.64M |
| Total operating expenses | 34.77M | 79.44M | 133.08M | 76.24M | 65.17M |
| Cost of revenue | - | 3.35M | 1.39M | - | - |
| Total other income expense net | 0.36M | -5.75M | -142.35M | 2.54M | 3.09M |
| Discontinued operations | 10.73M | -29.12M | -29.12M | -29.12M | - |
| Net income from continuing ops | -33.95M | -73.33M | -255.57M | -73.70M | -51.45M |
| Net income applicable to common shares | -23.21M | -73.33M | -255.57M | -95.18M | -74.16M |
| Breakdown | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 |
| Total assets | 97.69M | 40.76M | 67.05M | 93.74M | 79.17M |
| Other current assets | 2.66M | 7.19M | 0.34M | 5.45M | 1.38M |
| Total liab | 8.95M | 9.56M | 18.41M | 56.25M | 10.66M |
| Total stockholder equity | 88.73M | 31.20M | 48.64M | 37.49M | 68.51M |
| Other current liab | 5.76M | 6.96M | 11.55M | 0.10M | 0.48M |
| Common stock | 0.00M | 1.47M | 0.01M | 0.00M | 0.00M |
| Capital stock | 0.00M | 0.00M | 0.01M | 0.00M | 0.00M |
| Retained earnings | -691.34M | -662.74M | -639.52M | -566.20M | -184.34M |
| Other liab | - | - | - | 0.77M | 0.88M |
| Good will | - | - | - | 4.54M | - |
| Other assets | - | 2.48M | 3.51M | 4.90M | 0.74M |
| Cash | 30.67M | 30.91M | 42.25M | 57.56M | 30.78M |
| Total current liabilities | 7.54M | 9.35M | 18.41M | 21.45M | 10.66M |
| Current deferred revenue | - | - | - | 15.81M | 5.71M |
| Net debt | -30.46M | -31.26M | -41.90M | -22.78M | -30.08M |
| Short term debt | 0.12M | - | 0.35M | 0.76M | 0.70M |
| Short long term debt total | 0.21M | -0.35M | 0.35M | 34.78M | 0.70M |
| Other stockholder equity | 780.04M | 692.26M | 688.16M | 603.68M | 252.82M |
| Property plant equipment | - | - | 0.35M | 2.14M | 4.58M |
| Total current assets | 95.96M | 38.27M | 63.19M | 87.26M | 78.33M |
| Net tangible assets | - | 31.20M | 48.64M | 37.49M | 17.57M |
| Short term investments | 62.63M | - | 0.00M | 1.03M | 46.17M |
| Net receivables | - | 5.17M | 7.58M | 15.82M | 0.14M |
| Long term debt | - | - | - | 33.17M | - |
| Inventory | - | 0.10M | 7.29M | 7.40M | 1.36M |
| Accounts payable | 1.66M | 2.39M | 6.51M | 4.78M | 3.77M |
| Accumulated other comprehensive income | 0.03M | - | - | - | 0.02M |
| Common stock total equity | - | - | - | 0.00M | 0.00M |
| Non currrent assets other | 1.51M | 2.20M | 3.51M | 4.34M | 0.07M |
| Non current assets total | 1.72M | 2.48M | 3.86M | 6.48M | 0.84M |
| Capital lease obligations | 0.21M | 0.00M | 0.35M | 1.61M | 0.70M |
| Breakdown | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 | 2018-12-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 | 2018-12-31 |
| Investments | 15.67M | 1.03M | 89.11M | 41.37M | -33.88M |
| Change to liabilities | -8.68M | -2.67M | -12.97M | 18.05M | 0.24M |
| Total cashflows from investing activities | 15.67M | 1.03M | 89.11M | 41.87M | -11.76M |
| Net borrowings | - | -36.43M | -36.43M | 33.90M | 33.90M |
| Total cash from financing activities | 1.65M | 39.78M | 61.81M | 4.99M | 125.91M |
| Change to operating activities | -0.35M | -0.37M | -4.17M | -0.39M | -0.29M |
| Net income | -23.21M | -73.33M | -255.57M | -73.70M | -51.45M |
| Change in cash | -11.88M | -15.56M | 13.83M | -18.73M | 39.30M |
| Begin period cash flow | 42.85M | 58.42M | 44.58M | 49.51M | 10.21M |
| End period cash flow | 30.98M | 42.85M | 58.42M | 30.78M | 49.51M |
| Total cash from operating activities | -29.20M | -56.37M | -137.08M | -65.10M | -52.73M |
| Issuance of capital stock | 1.68M | 75.98M | 61.64M | 4.53M | 125.42M |
| Depreciation | 0.07M | 0.11M | 0.34M | 0.70M | 0.02M |
| Other cashflows from investing activities | 15.67M | 15.67M | 15.67M | 15.67M | - |
| Change to inventory | 0.10M | 0.11M | -6.05M | -1.36M | 2.76M |
| Change to account receivables | 11.21M | 7.71M | -17.14M | 0.37M | 0.79M |
| Other cashflows from financing activities | 0.18M | 0.23M | 0.17M | 0.47M | 0.50M |
| Change to netincome | -8.34M | 12.08M | 158.48M | 4.75M | 5.54M |
| Capital expenditures | 0.00M | 0.00M | 0.11M | 0.01M | 0.14M |
| Change in working capital | 2.28M | 4.78M | -40.33M | 1.89M | -4.17M |
| Stock based compensation | 4.30M | 8.08M | 18.10M | 6.70M | 3.64M |
| Other non cash items | -12.64M | 2.47M | 84.07M | -0.69M | -0.77M |
| Free cash flow | -29.20M | -56.37M | -137.19M | -65.11M | -52.87M |
Sector: Healthcare Industry: Biotechnology
|
Stock Name
|
Change
(USD) |
Price
(USD) |
Trailing
PE (x) |
Forward
PE (x) |
Price Sales
TTM (x) |
Price to Book Value (x)
|
Enterprise Value
to Revenue (x) |
Enterprise Value
to EBITDA (x) |
|---|---|---|---|---|---|---|---|---|
| NVO Novo Nordisk A/S |
-0.79 1.90% |
40.59 | 41.58 | 31.15 | 2.13 | 32.99 | 2.11 | 4.70 |
| VRTX Vertex Pharmaceuticals Inc |
-1.97 0.36% |
548.90 | 30.22 | 24.27 | 10.36 | 6.50 | 9.99 | 24.66 |
| REGN Regeneron Pharmaceuticals Inc |
-9.49 1.03% |
910.47 | 29.07 | 20.12 | 7.57 | 3.82 | 6.95 | 19.42 |
| ARGNF argenx SE |
- -% |
900.30 | 45.77 | 31.25 | 13.84 | 7.12 | 11.38 | 36.06 |
VYNE Therapeutics Inc., a clinical-stage biopharmaceutical company, focuses on developing proprietary and therapeutics for the treatment of immuno-inflammatory conditions. The company's lead product is VYN201, a locally administered pan- bromodomain and extra-terminal (BET) inhibitor soft drug to address diseases involving multiple, diverse inflammatory cell signaling pathways with low systemic exposure. It also develops VYN202, a BD2-selective oral small molecule BET inhibitor for the treatment of immuno-inflammatory indications. The company was formerly known as Menlo Therapeutics Inc. and changed its name to VYNE Therapeutics Inc. in September 2020. VYNE Therapeutics Inc. was founded in 2003 and is based in Bridgewater, New Jersey.
685 Route 202/206 N, Bridgewater, NJ, United States, 08807
800 775 7936
10
| Name | Title | Year Born |
|---|---|---|
| Mr. David T. Domzalski | CEO, Pres & Director | 1967 |
| Dr. Iain A. Stuart Ph.D. | Chief Scientific Officer | 1973 |
| Ms. Mutya Harsch J.D. | Gen. Counsel, Chief Legal Officer & Company Sec. | 1975 |
| Mr. Tyler Zeronda | CFO, Principal Accounting Officer & Treasurer | 1986 |
| Mr. David Schuz | Sr. VP of Intellectual Property | 1954 |
| Dr. Russell Elliott D.Phil. | Sr. VP of Pharmaceutical Devel. | 1966 |
| Dr. Darrell S. Rigel M.S., M.D., MS | Consultant | 1950 |
| Mr. David T. Domzalski | CEO, President & Director | 1967 |
| Ms. Mutya Harsch J.D. | General Counsel, Chief Legal Officer & Company Secretary | 1975 |
| Mr. Tyler Zeronda | CFO & Treasurer | 1987 |
Disclaimer - (*)This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.
Download a free report with stock ideas and industry insights for general information.
Download Free Report Now →
Basic Materials
-1.70%
Communication Services
-0.44%
Consumer Cyclical
-0.50%
Consumer Defensive
+0.08%
Energy
-0.07%
Financial Services
-0.35%
Financials
-2.20%
Healthcare
-0.95%
Industrials
-0.37%
Real Estate
-0.38%
Technology
-1.52%
Utilities
-0.57%
Note: Daily price change (%) by sector excluding stocks with +/-90% daily price change. Companies above $500 million market capitalization are considered.
Portfolio
Watchlist
Please wait processing your request...